AMD

– Age-related macular degeneration — also called macular degeneration, AMD or ARMD — is deterioration of the macula, which is the small central area of the retina of the eye that controls visual acuity. AMD is most common among the older white population, affecting more than 14 percent of age 80 and older.

Macular degeneration is diagnosed as either dry (non-neovascular) or wet (neovascular). Neovascular  refers to growth of new blood vessels in an area, such as the macula, where they are not supposed to be.

The dry form is more common than the wet form, with about 85 to 90 percent of AMD patients diagnosed with dry AMD. The wet form of the disease usually leads to more serious vision loss.

Lutein and Zeaxanthin can reduce the risk of dry AMD progressing to sight-threatening wet AMD.

For wet AMD, treatments aimed at stopping abnormal blood vessel growth include FDA-approved drugs called Lucentis, Eylea on label and Avastine off-label .

Intravitreal

Anti VEGF Injection

Dr. Blerina Kambo